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PENYELIDIKAN MENGENAI IMUNOASAI HOMOGEN BERASASKAN 
PEMINDAHAN TENAGA RESONANS FӦRSTER UNTUK PENENTUAN 
(R)-METADON 
 
ABSTRAK 
 Analisis ubatan biasanya dijalankan dengan menggunakan kaedah 
kromatografi yang tepat dan spesifik seperti GC-MS dan LC-MS. Kaedah tersebut 
diketahui mempunyai kepekaan dan spesifisiti yang tinggi. Walau bagaimanapun, 
kaedah tersebut memerlukan peralatan yang canggih dan kepakaran profesional 
untuk menjalankan analisis. Bagi menganalisis sampel yang banyak, kaedah analisis 
yang lebih mudah seperti imunoasai akan dijalankan sebelum pengesahan keputusan 
dengan menggunakan GC-MS dan LC-MS. Oleh itu, asai “high throughput screening” 
adalah penting untuk meningkatkan kecekapan analisis perubatan. Dalam kajian ini, 
ciri-ciri berpendarfluor pewarna organik, titik kuantum dan kelat lantanida akan 
dikenal pasti kemudian digunakan. Sebagai keputusan, imunoasai homogen 
berasaskan FRET dan TR-FRET yang baru telah dihasilkan dan diuji untuk 
mengesan (R)-metadon dalam serum manusia. Kepekatan (R)-metadon dalam 50 
pesakit MMT kemudian diuji. Kepekaan dan ketepatan asai yang dihasil kemudian 
dikaji dan disahkan dengan menggunakan kaedah LC-MS/MS. Hasil kajian juga 
menunjukkan bahawa terdapat kolerasi antara ketiga-tiga imunoasai dengan kaedah 
kromatografi. Nilai R
2
 daripada analisis regresi bagi imunoasai berasaskan FRET, 
imunoasai bersaskan “Point of Care – FRET” dan imunoasai berasaskan TR-FRET 
adalah R
2
 = 0.898, 0.797 dan 0.910  masing-masing. Dalam kajian ini,  imunoasai 
yang dihasilkan akan dibandingkan dengan ELISA dari segi kepekaan, cara 
kendalian dan tempoh masa asai. Secara keseluruhannya, keputusan menunjukkan 
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bahawa imunoasai homogen yang berasaskan FRET dan TR-FRET mempunyai 
kelebihan berbanding dengan ELISA, kerana masa analisis yang lebih singkat dan 
cara pengendalian yang lebih mudah. Namun demikian, antara ketiga-tiga imunoasai, 
imunoasai berasaskan TR-FRET adalah kaedah analisis yang terbaik berdasarkan 
ketepatan dan kepekaan analisis yang tinggi.  Berdasarkan keputusan ini, jelas 
menunjukkan bahawa imunoasai yang baru ini mempunyai potensi untuk digunakan 
sebagai salah satu alternatif antara asai “high throughput screening” dalam analisis 
perubatan. Selain itu, dapat dirumuskan bahawa titik kuantum tidak sesuai digunakan 
dalam kajian molekul ubat yang kecil, kerana titik kuantum didapati berinteraksi 
dengan molekul ubat yang kecil sama ada selepas konjugasi ataupun melalui 
penyerapan pasif. Oleh itu, kajian selanjutnya diperlukan untuk pemahaman antara 
interaksi tersebut.  
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DEVELOPMENT OF FӦRSTER RESONANCE ENERGY TRANSFER 
BASED HOMOGENEOUS IMMUNOASSAY FOR DETERMINATION OF 
(R)-METHADONE 
 
ABSTRACT 
Drug analysis is commonly performed using an accurate and specific 
chromatographic method, such as GC-MS and LC-MS. These methods are known to 
be highly sensitive and specific. However, they require sophisticated equipment and 
also skilled manpower for the analysis. For analysis of large number of samples, less 
descending methods like immunoassays are used prior to confirmation by GC-MS or 
LC-MS. Thus, high throughput screening is essential in increasing the efficiency of 
drug testing.  In this study, the fluorescence properties from various types of 
fluorescence materials, such as organic dyes, quantum dot and lanthanide chelates 
were investigated and employed. As a consequence, new FRET and TR-FRET based 
homogeneous competitive immunoassays were successfully designed and developed 
for detection of (R)-methadone in serum sample. Then, the concentrations of (R)-
methadone in the 50 MMT patient’s serums were tested. Consequently, the accuracy 
and sensitivity of the developed assays were studied and validated by using LC-
MS/MS method. Generally, comparison of the LC-MS/MS method with other three 
immunoassays methods showed adequate correlation. The regression analysis of 
FRET based immunoassay, point of care - FRET based immunoassay and TR-FRET 
based immunoassay are R
2 
= 0.898, 0.797 and 0.910, respectively. In this study, the 
developed FRET based assays were also compared with conventional ELISA method 
in terms of assay sensitivity, simplicity of handling and assay time. Overall results 
suggest that the reported homogeneous immunoassays advantageous over ELISA as 
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it required shorter assay time with easy handling. Nevertheless, comparison among 
these immunoassays, TR-FRET immunoassay is the best analytical method due to its 
higher accuracy and sufficient sensitivity. These results demonstrated the potential of 
the developed immunoassays as alternatives in high throughput screening method in 
drug testing. Besides, through this study, it was also found that quantum dots are not 
suitable to be used in small drug study as there are interactions between quantum dot 
and small drug molecules either after conjugation or via passive adsorption. 
Therefore, further studies are needed to deepen the understanding of these 
interactions. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Drug testing 
Drug abuse is an issue that brings many negative consequences to the community 
and also the individual (Meririnne et al., 2007). In order to protect the public welfare 
and support the enforcement of the law, testing for drugs in urine has become 
important in order to defeat abuses. Most drug testing is usually carried by using 
highly sensitive techniques typically chromatographic and mass spectrometric 
techniques. However, with the recent increase in the drug abuse cases and the 
number of drug types (Administration, 2014), more efficient drug testing approaches, 
especially using high throughput screening assays have started to penetrate into drug 
testing laboratories.  
 
The drug testing process starts by using low cost screening analysis as initial tests 
and suspect samples are further confirmed using a more accurate method such as 
chromatographic analysis and mass spectrometry (Kankaanpää et al., 2004). The 
common screening methods that are used in drug testing laboratories are thin-layer 
chromatography (TLC) and immunoassays.  
 
Thin-layer chromatography is a primary screening test that is low in cost and able to 
be rapidly performed by spotting the sample on a TLC plate (Kenyon et al., 1995). 
The results are reliable as identical drugs or analytes will always give same migration 
pattern (Rf value). Besides, it is also able to separate the target drug and its 
metabolite as spots on the plate. However, this method lacks of sensitivity and 
specificity. The accuracy of the result decreases when the concentration level of the 
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analyte is low. In addition, it only allows qualitative determination and frequently 
results in false positives (Schütz et al., 2006).  
 
On the other hand, immunoassays allow or both qualitative and quantitative analysis 
and is relatively sensitive (Hoofnagle and Wener, 2009). It does not use sophisticated 
equipment and immunoassays provides a flexible and rapid way to screen large 
number of samples in a short period of time  (Darwish, 2006). As immunoassays are 
one of the most cost effective ways for drug detection, it has become a preferred 
screening technique (Gan and Patel, 2013). 
 
1.2 Immunoassay 
Immunoassay is a diverse technique that utilizes the interaction of the antigen (target 
substances) with antibodies. The first immunoassay was published by Dr. Solomon 
Berson and Dr. Rosalyn Yalow for the analysis of insulin (Yalow and Berson, 1960). 
The radioimmunoassay (RIA) for insulin was clinically significant and Dr. Rosalyn 
became the co-winner for the Nobel Prize in Medicine/Physiology in 1977 (Wu, 
2006).   
 
Immunoassay is the measurement of the degree of binding between an antibody and 
a target analyte. To perform this measurement, labels such as radioactive isotopes, 
fluorescent tags or enzymes are usually used. The change in the reading of the label 
when bound to the antigen is the basis of measurement for the instrument. Generally, 
it can be performed in either heterogeneous or homogenous phase (Jiang et al., 2011).  
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In a heterogeneous system, either antibodies or antigens will be immobilized onto a 
solid phase, and the analytes or the detection molecules (typically in aqueous phase) 
are added sequentially. In order to remove the free analytes from antibody bound 
analytes, separation or washing steps are performed. The signal from the system is 
then obtained from the measurement of the labelled antigen that is bound on the solid 
surface (Figure 1.1).  
 
Figure 1.1: Schematics of the basic principle of heterogeneous immunoassay.  
 
In contrast to the heterogeneous system, homogeneous phase analysis generally 
involves the conjugation of the biomolecules to the labelling materials that is used 
for signal enhancement. The formation of immunocomplex is performed in a solution 
phase by adding the analyte and labelled analyte with the antibodies. The binding of 
the labelled analyte with the antibody will then alter the signal of the labelled analyte 
and hence reports the outcome (Figure 1.2) (Dasgupta and Wahed, 2014).  
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Figure 1.2: Schematics of the basic principle of homogeneous immunoassay. 
 
1.2.1 Immunoassay system in drug testing 
To date, scientists have utilized the unique features of immunoreactions (capable of 
drug detection in complexes samples) in development of immunoassay for used in 
drug testing. There are 4 main types of detection methods that are commonly used in 
drug screening.  
 
1.2.1(a) Radioimmunoassay (RIA) 
Radioimmunoassay is a heterogeneous assay system that is based on the 
measurement of the quantity of radioactive isotopes that are bound to the antibodies. 
In the assay, the free antigen will compete with the isotope labelled antigen to bind to 
the antibody. After the reaction, the unbound analyte and analyte-indicator will be 
removed from the system through a washing or separation step. RIA commonly 
utilizes iodine-125 as the indicator for signal enhancement. This isotope exhibits a 
relatively short life time of 60 days and frequent resynthesizing of the reagent is 
required (Weeks et al., 2013).  
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However, the issue of radioactive waste disposal has led to the recent drop in 
popularity of RIA usage. Besides that, the specialized and high cost equipment is 
needed for the measurement. Thus, RIA is gradually being replaced by other easily 
automated immunoassay systems in spite of it being able to produce accurate results 
(Goldsmith, 1975). 
 
1.2.1(b) Enzyme immunoassay (EIA) 
Enzyme immunoassay is the further improvement for the RIA system as it is based 
on the same reaction principles. Generally, the desired target drug analytes are 
labelled to enzymes instead of radioactive isotopes in the assay system. The signal is 
later detected by the after competitive reaction between the drug labelled enzyme and 
free drug molecules. To date, there are both heterogeneous and homogeneous EIA 
assay formats available in the market (Lequin, 2005).  
 
Many enzyme based immunoassay systems have been developed and 
commercialized for drug screening purpose, such as Enzyme-Linked Immunosorbent 
Assay (ELISA), Enzyme Multiplied Immunoassay Technique (EMIT) and Cloned 
Enzyme Donor Immunoassay (CEDIA) (O'Kennedy et al., 1990; Porstmann and 
Kiessig, 1992). These assays were designed by using different labels for signal 
enhancement and the format of these assays is summarized in Table 1.1. However, 
pros and cons of the different platforms have to be considered when choosing the 
right platform for the desired sensitivity and specificity of analysis.  
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Table 1.1: Commercially available EIA assay format.  
Immunoassay Format Enzyme 
ELISA Heterogeneous Alkaline phosphatase (AP) & 
Horseradish peroxidase (HRP) 
EMIT Homogeneous glucose 6-phosphate dehydrogenase 
enzyme 
CEDIA Homogeneous beta-galactosidase 
 
1.2.1(c) Fluoroimmunoassay (FIA) & Fluorescence polarization immunoassay 
(FPIA) 
Just like other immunoassays, fluoroimmunoassay also relies on the interaction of 
fluorescent material (typically lanthanide chelates complexes) labelled proteins with 
the target molecules. It can be performed in both homogeneous and heterogeneous 
phase which typically involve the usage of secondary antibody. The fluorescence 
properties which are altered by the interaction between the antibodies and antigens 
will report the outcome.  Due to the high sensitivity of the assay, the applications of 
fluoroimmunoassays are tremendous and it is readily available in the market as 
dissociation enhanced lanthanide fluoroimmunoassays (DELFIA) or time-resolved 
fluoroimmunassays (TRFIA) (Hemmila, 1985; Vohr, 2005).  
 
Figure 1.3: Assay Principle of TRFIA. (Figure adapted from Chen et. al., (2015)) 
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There is another type of fluorescent labelled based immunoassay in the market which 
is called fluorescence polarization immunoassay (FPIA). FPIA is performed in 
homogeneous phase and the detection signal of FPIA is obtained through the 
behaviour of the fluorophore labelled antigen under the plane-polarized light (Figure 
1.4). The interactions of the free drug molecule in the samples, fluorophore labelled 
reagents and antibodies can be correlated to the drug levels in the samples through a 
calibration curve (Routledge and Hutchings, 2013). 
 
Figure 1.4: Assay Principle of FPIA. (Figure adapted from Oberleitner et. al.(2015)) 
 
1.2.1(d) Lateral flow immunoassay (LFIA) 
Lateral flow immunoassay, also called immunochromatographic tests, is a specially 
designed point of care (POC) testing device. A recent published review had 
emphasized its sensitivity, selectivity and ease of use of this assay method (Sajid et 
al., 2015; Posthuma-Trumpie et al., 2009). LFIA consists of several assay formats 
where the formats are chosen depending on the analyte. The labelling materials that 
are often used in FLIA are nanoparticles such as colloidal gold, iron oxide magnetic 
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particles, fluorescent and luminescent materials, colloidal carbon and enzyme. These 
labelling materials normally exhibit high stability and also able to detect at low 
concentration (Sajid et al., 2015). 
 
In LFIA, there is a surface layer (sample pad) to collect the sample and a layer of 
conjugate pad that is consists of desired labelled biomolecules. The added sample 
will travel through the conjugate pad and interact with the labelled biomolecules in it. 
Together, the sample and labelled molecules will then continue to flow along the 
strip (detection zone) up to the absorbent pad.  This will allow chromatographic 
separation of the excess target drugs and hence increase the sensitivity of the assay. 
The typical configuration of lateral flow immunoassay is shown in Figure 1.5.  
 
 
Figure 1.5: Typical configuration of lateral flow immunoassay. (Figure adapted 
from O’Farrell et. al., (2009)) 
 
 
1.2.2 Heterogeneous vs homogeneous immunoassay 
As mentioned previously, a separation step (or a washing step) prior to signal 
measurement is required in heterogeneous assays. Consequently, the matrices or 
interferences are able to be removed and hence increasing the sensitivity of the assay. 
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However, homogeneous immunoassays are more user friendly and have faster assay 
time as it does not require the separation step (Schütz et al., 2006; Wild, 2013). 
Besides that, it also allows the analysis of complex samples, such as unprocessed 
blood and urine samples (Pei et al., 2013). These unique features have fascinated 
researchers in utilizing homogeneous immunoassay in drug testing. As such, Förster 
Resonance Energy Transfer technique that is based on fluorescent labelled offers a 
good prospect in development of brand new homogeneous immunoassay.  
 
1.3 Förster Resonance Energy Transfer (FRET) 
Förster resonance energy transfer (FRET) is a theory of molecular resonance energy 
transfer that was published by Theodor Förster in 1946 (Theodor, 1946). This theory 
described the non-radiative interaction of an electronic excited molecule with the 
near-neighbour molecule within distance of 10 – 100 Å (Theodor, 1948; Clegg, 
1995).  
 
When there is a matching energy frequency at the vibration level between two 
molecules, it can be said that there is a resonance condition between these two 
molecules. Hence, the energy which has the same frequency between these two near-
neighbour molecules is able to transfer non-radiatively from one to another upon 
excitation. This energy transmission typically occurs from the donor molecules to the 
acceptor molecules (Schmid and Sitte, 2003). The Jablonski diagram of the energy 
transfer pathway is shown in Figure 1.6.  
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Figure 1.6: Jablonski diagram of FRET process. (Figure adapted from Szollosi et 
al.,(1998)) 
 
This energy transmission is the result of long range dipole-dipole interactions 
between the donor and acceptor molecules. This resonance energy transfer can 
clearly be observed when it occurs between a fluorophore and an acceptor molecule. 
As a result of this energy transfer, the donor molecule’s fluorescence intensity and 
excited lifetime is reduced. Subsequently, the acceptor molecule will be sensitized 
and its fluorescence intensity will increase (Figure 1.8). This pair of interacting 
fluorescent molecules is referred to as donor/acceptor pair or FRET dye pair 
(Masters, 2014). 
 
1.3.1 FRET Efficiency 
The signal measurement for FRET analysis is done by calculating the amount of 
quanta (energy) being transferred from donor to acceptor, which is called FRET 
efficiency (Clegg, 1995). FRET efficiency can be calculated either by measuring the 
change in lifetime or the intensities changes of the donor fluorophore as defined in 
Equation 1.1 below: 
     
   
  
    
   
  
 [1.1]               
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where E is the quantum yield of energy transferred,  DA is the lifetime of the donor 
with the acceptor and  D is the lifetime of the donor without the acceptor; FDA is the 
emission intensity of the donor with the acceptor and FD is the emission intensity of 
the donor without the acceptor  (Lakowicz, 2006a). 
 
1.3.2 Factors that affect FRET efficiency 
There are a few factors that need to be considered and satisfied to facilitate FRET. 
 
1.3.2(a) Distance between donor-acceptor molecules 
FRET strongly depends on the distance between the donor and acceptor molecules. It 
only happens when the two interacting molecules are sufficiently close, typically 
within 10 – 100 Å (Hayward et al., 2010). Förster defined the relationship between 
the distance between the two interacting molecules with the FRET efficiency in the 
equation below. 
   
  
 
  
    
 
where Ro is the Förster radius where 50% of energy is transferred; while r is the 
distance between donor and acceptor molecule (Figure 1.7).  
 
Figure 1.7: Relationship between FRET efficiency with donor-acceptor distance. 
(Figure adapted from Lakowicz (2006a)) 
[1.2]               
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Ro may also be affected by other parameters and their relationship as shown in the 
equation below. 
 
  
   
              
        
            
   
 
 
 
 
where κ2 is the orientation factor, QD  is the quantum yield of the donor, N is the 
Avogadro’s number, n is the refractive index of the medium, FD(λ) is the corrected 
fluorescence intensity of donor from λ to λ+   with the total intensity normalized to 
unity.    λ  is the extinction coefficient of the acceptor at λ nm in unit M
-1
cm
-1
 
(Lakowicz, 2006a). 
 
1.3.2(b) Spectral overlap of donor and acceptor  
The matching of emission and excitation spectra (spectral overlap) between donor 
molecule and acceptor molecule is necessary in order for FRET to occur. Generally, 
the donor molecule emits at a shorter wavelength, and this emission wavelength 
needs to overlap with the excitation wavelength of the acceptor molecule. The degree 
of spectral overlapping may affect the efficiency of energy transmission. The FRET 
process occurs significantly when the achieved overlap is more than 30 (Stryer, 
1978). The degree of spectral overlap which is also referred as spectral overlap 
integral (J) can be calculated through the following equation.  
 
              
 
 
        
where FD (λ) is the corrected fluorescence intensity of the donor from λ to λ+   with 
the total intensity normalized to unity,    λ  is the extinction coefficient of the 
[1.3]               
[1.4]               
13 
 
acceptor at λ nm in unit M-1cm-1(Lakowicz, 2006a). The spectral characteristic and 
the changes of the intensity of the FRET pair after FRET process is summarized in 
Figure 1.8 below. 
 
Figure 1.8: Spectral characteristic and the changes of intensity of FRET pair after 
FRET process. (Figure adapted from Szollosi et al.,(1998)) 
 
1.3.2(c) Transition dipole orientations of the donor and acceptor 
The transition dipole orientation of the donor and the acceptor in the FRET system is 
expressed as the orientation factor, κ2. It is one of the important parameters in the 
calculation of Förster radii (Khrenova et al., 2015). In order to FRET, the transition 
dipole of the donor molecules and the acceptor molecules have to be approximately 
parallel. The transition conformation of the donor and acceptor molecules can vary 
from range 0 ≤ κ2 ≤ 4 (Loura, 2012).  
 
Generally, κ2 is always assumed equal to be 2/3 because this is the value for the 
transition orientation of donor or acceptor species where it is randomized by 
rotational diffusion before energy transfer. In fact, the orientations of donor and 
acceptor species (macromolecules in this case) are likely to be randomized when 
tagged with fluorophores. In addition to that, research have also proved that the 
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errors when calculating the distance is less than 35% when assuming κ2 = 2/3. This 
finding further strengthens this assumption (Lakowicz, 2006a). 
 
1.3.3 Fluorescent materials for used in FRET system 
One of the important criteria of FRET is that it explains the pathway of the excited 
photon in the donor molecule returning to its ground state through the transfer of its 
excitation energy to another proximate molecule (Chirio-Lebrun and Prats, 1998). 
This process generally involves at least one fluorescent material as the donor 
molecule and an acceptor molecule that must be able to absorb the energy from 
donor at the donor’s emission wavelength. Although the acceptor molecule does not 
necessarily have to be fluorescent, most users however are likely to use fluorophore 
as donor and acceptor in their FRET system (Cardullo, 2007). In general, there are 
several fluorescent materials that are being utilized in FRET system. The details are 
described below: 
 
1.3.3(a) Organic dyes  
Organic dyes also referred to as fluorescent dyes or fluorophores, are small organic 
molecules of 20 - 100 atoms that contain polyaromatic hydrocarbons or heterocycles 
in their molecular structure. The optical properties of organics dyes come from the 
nature of the electron transition over the fluorophore. Briefly, emission happen when 
there is formation of charge transfer (CT) state (CT dyes), transmission of 
delocalized electron between energy band or electronic state (mesomeric dyes) over 
the fluorophore (Resch-Genger et al., 2010). 
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Organics dyes are categorised under the group of extrinsic fluorescent materials. It is 
able to absorb and emit light readily in the longer wavelength, which could be in 
ultraviolet (UV), visible range (VIS) and near-infrared (NIR) region. The common 
structures of commercially available fluorescent dyes that absorb and emit at 
different wavelengths along with the spectral region is shown in Figure 1.9 (Sauer et 
al., 2011). 
 
 
 
Figure 1.9: (a) Molecular structures and (b) the maxima absorbance and emission of 
common fluorescent dyes. (Figure adapted from Medintz et al. (2005) and Sapsford 
et  al., (2006)) 
(a) 
(b) 
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Fluorophores are one of the powerful tools in biological research. They are popular 
as they have a high extinction coefficient (10,000 – 100,000 M-1cm-1) and a high 
quantum yield (Lakowicz, 2006d). Consequently, organic dyes are excellent in 
absorbing light and able emit fluorescence efficiently. Also, their fluorescence life 
time ranges between 1 – 10 ns and they decay at a mono-exponential rate (Resch-
Genger et al., 2008; Lakowicz, 2006d).  
 
Each fluorescent dye has its own unique fluorescence properties where their 
fluorescence intensity and also wavelength can be altered readily by solvent polarity, 
pH, temperature and also voltage of the environment (Sauer et al., 2011; Sousa et al., 
1996). Generally, organic dyes are very soluble and stable in water. There are, 
however, some fluorescent dyes like cyanine dyes and certain fluorescein derivatives 
that have low solubility in water. Furthermore, reactive functional groups can often 
be found in fluorescent dyes (Sapsford et al., 2006). This enables the conjugation of 
fluorophores to biomolecules to be easily carried out and further extend their 
applications, especially in FRET assays.  
 
Unfortunately, most fluorescent dyes have low photochemical stability. They 
decompose easily and experience fading of fluorescence intensity when exposed 
continuously to light or upon repeated excitation. This phenomenon is also called 
photobleaching. Besides, the broad absorption/emission profile and small stoke shift 
may lead to high background reading and spectral bleed through. This spectral bleed 
through will lead to the detection of fluorescence from an undesired fluorophore 
(typically from the second fluorophore) and will definitely complicate the FRET 
analysis (Feng et al., 2006; Sapsford et al., 2006).  
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Despite these drawbacks, fluorophores are indispensable in applications in biology. 
The use of organics dyes is cost effective and the ease of bioconjugation reduces the 
burden on the investigators. Furthermore, new approaches on producing novel 
organic dyes with better chemical and optical properties may also further extend the 
use of organic dyes in FRET analysis (Bai et al., 2007; Zhao et al., 2013). 
 
1.3.3(b) Inorganic materials 
Inorganic fluorescent materials are usually associated with the doping of relatively 
inert matrices such as zinc sulphide or cadmium sulphide with activator metallic ions 
such as transition or rare earth elements (Williams, 1980). Inorganic fluorescent 
materials have broad stokes shift and they usually need to be excited at ultraviolet or 
near visible region. Besides that, they also display longer fluorescence lifetime when 
compared to organics dyes. These unique features have enhanced the usage of 
inorganic fluorescent materials in FRET analysis (Lakowicz, 2006d). They are 
generally mildly toxic. Among all inorganic fluorescent materials, quantum dots and 
lanthanide complexes are frequently used by researchers in FRET studies. The 
details are described as below. 
 
1.3.3(b)(i) Quantum dots 
Quantum dots are semiconductor nanocrystals that are composed of an inorganic 
core and an outer layer which is normally capped with a layer of surfactant 
molecules (ligands) or metal shell in order to avoid agglomeration (Reiss, 2008). 
Generally, the quantum dots’ inorganic core can be made from semiconductor metals, 
alloys and other metals such as gold. The inorganic core normally contain a tiny 
droplet of free electrons (Ghasemi et al., 2009) and they are in spherical shape with 
diameters ranging from 1 to 10 nm.  
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Figure 1.10: Structure of quantum dots. (Figure adapted from (Johnston, 2015)) 
 
These relatively small particle size enable quantum dots to display special electronic 
properties which is referred as quantum confinement effect (Frasco and Chaniotakis, 
2009). As the particle sizes reduced down to a few nanometers, the wavelength of the 
electron (Bohr radius) becomes bigger than the nanocrystals. Hence, the confining 
dimension of the electrons decreases and these electrons then respond to the changes 
in its energy levels. Subsequently, the formation of energy level structure changes 
from band-like levels (typical bulk semiconductor energetic structure) into discrete-
like levels (discrete molecules energy level).  
 
These unusual situations cause the formation of larger spacing between the energy 
bands (conduction and valence band) and ultimately the band gap energy level will 
increase. As such, the movement of electrons between two energy levels lead to the 
formation of exciton (Figure 1.11), which is also referred to as electron-hole pairs 
(Reiss, 2008; Feng et al., 2006).  
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The optical properties of quantum dots are the result of the movement of electrons 
between the valence band and the conduction band (Figure 1.11). The 3D quantum 
confinement of the electrons and holes (exciton) enhances their optical properties 
through the controlling of the size of the crystal structure. Also, quantum dots show 
large stoke shift by displaying continuous absorption spectra from ultraviolet to 
visible region and show narrow size-tunable emission spectra width (Valeur and 
Berberan-Santos, 2012; Reiss et al., 2009; Resch-Genger et al., 2008).  
 
Different elements and composition may lead to different chemical and physical 
properties of quantum dots (Figure 1.12). Besides that, the inorganic shell that is 
coated at the outer layer of the core of the quantum dots have further enhanced the 
stability of the quantum dots towards photodegradation (Rizvi et al., 2010; Baranov 
et al., 2003) and provide higher photochemical stability in comparison to organic 
dyes (Resch-Genger et al., 2008). Quantum dots exhibits longer fluorescence life 
times which is in range of 10 – 100 ns and typically experience a multi-exponential 
decay rate.  
 
 
Figure 1.11: Formation of exciton and its optical properties. 
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All these characteristics are able to broaden the usage of quantum dots in many 
applications, such as optical coding, biosensor and imaging, photoelectrochemistry 
application and also as FRET donor (Figure 1.12).  
 
 
Figure 1.12: The relationship between quantum dot core materials vs its emission 
wavelength and its applications. (Figure adapted from Medintz, et al., (2005))  
 
 
1.3.3(b)(ii) Lanthanides  
Lanthanide elements (Ln) also referred as rare earth elements (RE), are elements 
with atomic numbers ranging from 57 to 71 (from lanthanum to lutetium). They are 
also known as f-block elements with the general electronic configurations of [Xe]4f 
n-1
5d
1
6f 
2
. They exhibit metal-like properties and a stable +3 oxidation state (Huang 
and Bian, 2010).  
 
The trivalent lanthanide ions have unfilled 4f shells, and thus different energy levels 
are generated through different arrangements of electrons in the 4f shell. 
Consequently, numerous absorption and emission spectra ranging from UV to visible 
and near-infrared (NIR) can be generated through the electron transition between the 
various energy levels (Figure 1.13). These 4f electron transitions make most 
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lanthanides ions luminescent and exhibit line like emission spectra (Bunzli and 
Piguet, 2005; Huang and Bian, 2010; Binnemans, 2009; Hemmila and Laitala, 2005). 
 
 
Figure 1.13: Partial energy diagrams for the lanthanides aquo ions. (Figure adapted 
from Bunzli and Piguet (2005)) 
 
However, the usage of lanthanide ions is limited due to their low molar absorption 
coefficients (typically less than 10 M
-1
cm
-1
). Hence, lanthanide ions are often 
coupled with intense absorption organic chromophores in order to stimulate the 
antenna effect. Here, the organic chromophore will absorb the excitation energy, and 
then transfer this energy to the lanthanide ion by intramolecular energy transfer. The 
lanthanide ions will then be sensitized and emit light at a well defined wavelength 
(Binnemans, 2009; Bunzli and Piguet, 2005; Chen and Xu, 2010; Matsumoto et al., 
2002; Hemmila and Laitala, 2005) (Figure 1.14).   This phenomenon also causes 
lanthanide chelates to exist longer fluorescence lifetimes (10
-2
 – 10-6 s) as compared 
to conventional fluorophores (10
-8 – 10-10 s) (Huang and Bian, 2010).  
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Figure 1.14: Energy pathway in sensitization of lanthanide chelate. (Bunzli and 
Piguet, 2005) 
 
These unique luminescent features of lanthanide chelates have fascinated researchers 
and help expand its applications such as electronic display to biological assays in 
biomedical applications (Selvin, 2002; Werts, 2005).   Among all the lanthanide 
chelates, europium and terbium have highest emission intensity in the visible region. 
Thus, they have gained a lot of popularity in bioanalytical applications especially in 
the development of time resolved – FRET (TR – FRET) based assay (Sapsford et al., 
2006).  
 
Scientists have reported that there are a few advantages when utilizing lanthanide 
chelates as donor in FRET system. Firstly, the line-like emission spectra and long 
decay time of lanthanide chelate reduces the background fluorescence effects. 
Furthermore, the long decay time also enhances efficient dynamic energy transfer 
and diminishes the orientational factor effect (κ2 value) in FRET system (Hemmila 
and Laitala, 2005).  
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Also, the environment polarity-independent spectral properties that make the 
luminescence intensity and peak free from solvent polarity can also further enhance 
the usage of lanthanide in development of TR-FRET based assay (Lakowicz, 2006d). 
In addition, the broad peak like emission spectra of lanthanide chelates had increases 
the possibility of spectral overlapping and allow a wide range of acceptor dyes to 
couple with it (Sapsford et al., 2006). Consequently, assay sensitivity can be 
increased.  
 
In view of this, a lot of efforts have been made by researchers to utilized lanthanide 
chelates in TR-FRET studies. A large number of conjugatable chelators that are able 
to displace the bound water molecules have been synthesised and described 
(Lakowicz, 2006d). However, there are still some uncertainties when using the 
currently available chelators (Sapsford et al., 2006). Thus, careful investigation is 
still needed when using lanthanide chelates in TR-FRET studies. 
 
1.3.3(c) Fluorophore of biological origin 
Unlike organic or inorganic fluorophores, fluorophores of biological origin are 
intrinsic fluorophores with natural fluorescence. Usually, they are enzymatic 
cofactors such as nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FAD) or fluorescent proteins such as green and yellow fluorescent 
proteins (GFP, YFP). The usage of these intrinsic fluorescent compounds in FRET 
analysis were always emphasized (Sapsford et al., 2006). 
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Fluorescent proteins contain aromatic amino acid residues such as tryptophan (trp), 
tyrosine (tyr) and phenylalanine (phe) (Figure 1.15) and these enhance their 
fluorescence properties (Lakowicz, 2006b). These biological fluorescent compounds 
features strong absorbance at UV region and emission at VIS region with a 
fluorescence lifetime of not more than 7 ns. Compared to organic or inorganic 
fluorophores, fluorescent proteins are known to have lower quantum yield (<0.01 – 
0.35) and poor photo stability (Sauer et al., 2011). These features somehow limit the 
usage of fluorescent proteins in biological applications. 
 
   
Figure 1.15: Chemical structure of aromatic amino acids in fluorescent proteins. 
 
Several disadvantages are observed when using fluorescent protein in FRET analysis. 
The big protein size (25 – 30 kDa or larger) and the broad absorbance and emission 
spectra will lead to the cross talk effect (also terms as spectral bleed through) and 
ultimately decrease the FRET efficiency. In addition, the  restricted excitation region 
of the fluorescent proteins confine the FRET donor-acceptor to be paired only in the 
UV region (Sapsford et al., 2006). Furthermore, the interaction between these 
fluorescent proteins with other fluorescent proteins may lead to self-quenching in the 
fluorescence intensity during FRET analysis (Piston and Kremers, 2007). 
 
